Hims & Hers Health (NYSE:HIMS) Rating Increased to Buy at Needham & Company LLC

Posted by Don Miller on Mar 9th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) was upgraded by research analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm presently has a $30.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 35.44% from the stock’s previous close.

Several other analysts have also weighed in on the company. Evercore set a $24.00 target price on shares of Hims & Hers Health in a report on Tuesday, February 24th. TD Cowen reduced their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Hims & Hers Health and gave the company a “hold” rating in a research note on Tuesday, February 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $29.77.

Check Out Our Latest Report on HIMS

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $6.41 during midday trading on Monday, hitting $22.15. 104,888,658 shares of the stock were exchanged, compared to its average volume of 29,553,262. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The stock has a market cap of $5.05 billion, a P/E ratio of 43.43, a PEG ratio of 3.01 and a beta of 2.55. The company has a 50 day moving average price of $24.75 and a 200-day moving average price of $38.05. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.11 EPS. On average, research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has authorized a share repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 82,963 shares of company stock valued at $2,944,621 in the last 90 days. 13.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter worth $30,000. Envestnet Asset Management Inc. increased its holdings in shares of Hims & Hers Health by 41.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 83,844 shares of the company’s stock valued at $4,180,000 after acquiring an additional 24,726 shares during the period. Bank of New York Mellon Corp grew its holdings in Hims & Hers Health by 5.2% during the second quarter. Bank of New York Mellon Corp now owns 1,325,567 shares of the company’s stock worth $66,080,000 after acquiring an additional 65,275 shares during the period. Finally, AE Wealth Management LLC purchased a new position in Hims & Hers Health in the second quarter valued at about $292,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Novo Nordisk agreed to sell Wegovy and Ozempic via Hims & Hers and dropped its lawsuit, formally ending the public dispute and clearing a legal overhang that had pressured the stock. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
Positive Sentiment: Hims & Hers and Novo announced a collaboration to bring FDA‑approved GLP‑1 treatments (injectable and oral semaglutide options) to HIMS’ U.S. platform, representing a strategic pivot into high‑growth obesity care. Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
Positive Sentiment: Market reaction: multiple outlets report an outsized rally (pre‑market and early trading), reflecting investor relief and bullish positioning on HIMS’ access to GLP‑1 demand. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
Neutral Sentiment: Context and quick takes: several financial outlets summarize the deal and market implications; analysts will need time to model revenue/earnings impact because commercial terms were not disclosed. Hims and Hers Stock Pops on a Deal With Rival Novo Nordisk—What You Need to Know
Neutral Sentiment: Market commentary: traders noted this could be HIMS’ biggest one‑day gain ever as the company shifts from selling compounded alternatives to distributing branded GLP‑1s via its platform. HIMS Stock Eyes Best Day Ever After Dispute Dissolution
Negative Sentiment: Risks and limits: Novo retained the right to revive litigation if terms are breached, and HIMS agreed to stop promoting compounded GLP‑1 products and to sell Novo’s drugs at parity with other telehealth platforms — moves that could cap margin upside and leave commercial economics unclear. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.